Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2025Open Access

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

MNM. NguyenMJMark JelinekASArjun Singh

Discussion

Loading...

Member takes

Overview

Phase II study shows modest anti-tumor activity of ivosidenib and nivolumab in patients with advanced IDH1 solid tumors, suggesting further exploration is needed.

Key Points

  • The combination of ivosidenib and nivolumab showed a primary endpoint achievement of 20% in advanced mIDH1 solid tumors.
  • Despite modest overall response rates, pharmacodynamic studies indicated a significant reduction in plasma (R)-2HG levels correlating with clinical benefit.
  • A total of 15 patients were treated, revealing safety concerns such as leukopenia and rash in 67% of cases.
  • Translational data support the hypothesis for further trials combining IDH1 inhibitors with immune-checkpoint therapy.

Cite This Study

Nguyen et al. (2025) studied this question.

synapsesocial.com/papers/689a0614e6551bb0af8cd6c0https://doi.org/10.1101/2025.07.19.25331848
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations
  2. 2P12.23.B IDH INHIBITION AT RELAPSE?2025
  3. 3Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study2025 · 4 citations
  4. 4Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms2025
  5. 5Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome2025